Curated News
By: NewsRamp Editorial Staff
August 06, 2024
Clene (NASDAQ: CLNN) to Present at Canaccord Genuity 44th Annual Growth Conference
Discuss on Reddit
Discuss on LinkedInTLDR
- Investors can gain insight into Clene's innovative approach to treating neurodegenerative diseases at the Canaccord Genuity 44th Annual Growth Conference.
- Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
- Clene's research is dedicated to improving the lives of those with neurodegenerative diseases, offering hope for a better future.
- Clene Inc. is set to present at the Canaccord Genuity 44th Annual Growth Conference, providing an opportunity to learn about cutting-edge treatments.
Impact - Why it Matters
This news highlights Clene's commitment to developing innovative therapies for neurodegenerative diseases. Investors and individuals impacted by ALS and MS may gain valuable insights from the company's presentation.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company is focused on treating neurodegenerative diseases, including ALS and MS. The presentation is scheduled for August 13, 2024, at 11:30 a.m. EST. To view the live webcast, visit https://ibn.fm/uGo0W.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) to Present at Canaccord Genuity 44th Annual Growth Conference
